FrancophonIA/ELRC3.0 huggingface dataset:
English: The inter-subject variability (coefficient of variation, %) in haloperidol clearance was estimated to be 44% in a population pharmacokinetic analysis in patients with schizophrenia.
Maltese: Il-varjabilità bejn l-individwi (koeffiċjent ta' varjazzjoni, %) fit-tneħħija ta' haloperidol kienet stmata li hija 44% fl-analiżi farmakokinetika ta' popolazzjoni f'pazjenti bl-iskiżofrenja.
English: • Reported in clinical studies with haloperidol decanoate and relate to the active moiety.
Maltese: • Irrappurtati fi studji kliniċi b'haloperidol decanoate u jikkonċernaw il-parti attiva.
English: Other medicines and Haldol
Maltese: Mediċini oħra u Haldol
English: • 5 mg intramuscularly.
Maltese: • 5 mg minn ġol-muskolu.
English: • 1 to 2 mg intramuscularly.
Maltese: • 1 mg sa 2 mg minn ġol-muskolu.
English: The safety of haloperidol was evaluated in 284 haloperidol-treated patients who participated in 3 placebo-controlled clinical studies and in 1295 haloperidol-treated patients who participated in 16 double-blind active comparator-controlled clinical studies.
Maltese: .8 Effetti mhux mixtieqa Is-sigurtà ta' haloperidol ġiet ivvalutata f'284 pazjent ittrattati b'haloperidol li pparteċipaw fi 3 studji kliniċi kkontrollati bil-plaċebo u f'1,295 pazjent ittrattati b'haloperidol li pparteċipaw f'16-il studju kliniku kkontrollati b'kumparatur attiv fejn la l-investigaturi u lanqas l-individwi ma kienu jafu liema sustanza qed tintuża.
English: 5 drops
Maltese: 5 qatriet
English: • Acute treatment of delirium when non-pharmacological treatments have failed.
Maltese: • Trattament akut ta' delirju meta trattamenti mhux farmakoloġiċi jkunu fallew.
English: Cholestasis
Maltese: Rabdomijolisis
English: The effect of CYP3A4 inhibition and of decreased CYP2D6 enzyme activity may be additive (see section 5.2).
Maltese: L-effett ta' inibizzjoni ta' CYP3A4 u ta' tnaqqis fl-attività tal-enzima CYP2D6 jista' jkun addittiv (ara sezzjoni 5.2).
English: • High body temperature
Maltese: • Temperatura għolja tal-ġisem
English: • Tic disorders, including Tourette's syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.
Maltese: • Disturbi ta' tik, inkluż is-sindrom ta' Tourette, fi tfal u adolexxenti li għandhom minn 10 snin sa 17-il sena b'indeboliment sever wara li trattamenti edukattivi, psikoloġiċi u trattamenti farmakoloġiċi oħra jkunu fallew.
English: • Your dose will normally be between 0.5 mg and 10 mg each day.
Maltese: • Id-doża tiegħek is-soltu tkun bejn 0.5 mg u 10 mg kuljum.
English: 10 drops
Maltese: 10 qatriet
English: Table 5 lists adverse reactions as follows:
Maltese: Tabella 5 telenka r-reazzjonijiet avversi kif ġej:
English: • 1 to 10 mg intramuscularly.
Maltese: • 1 mg sa 10 mg minn ġol-muskolu.
English: • It is recommended to assess the individual benefit-risk when considering doses above 3 mg/day.
Maltese: • Huwa rrakkomandat li jiġi stmat il-benefiċċu u r-riskju individwali meta jitqiesu doża ta' aktar minn 3 mg/kuljum.
English: HALDOL and associated names (see Annex I) 1 mg tablets HALDOL and associated names (see Annex I) 2 mg tablets HALDOL and associated names (see Annex I) 4 mg tablets HALDOL and associated names (see Annex I) 5 mg tablets HALDOL and associated names (see Annex I) 10 mg tablets HALDOL and associated names (see Annex I) 20 mg tablets HALDOL and associated names (see Annex I) 2 mg/ml oral solution HALDOL and associated names (see Annex I) 10 mg/ml oral solution
Maltese: HALDOL u ismijiet assoċjati (ara Anness I) 1 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 2 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 4 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 5 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 10 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 20 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 2 mg/ml soluzzjoni orali HALDOL u ismijiet assoċjati (ara Anness I) 10 mg/ml soluzzjoni orali
English: Table 5: Adverse reactions
Maltese: Tabella 5:
English: • Attention deficit hyperactivity disorder (ADHD) or narcolepsy (known as ‘stimulants')
Maltese: • Għal reazzjonijiet allerġiċi severi (adrenalina) • Għad-disturb ta' nuqqas ta' attenzjoni u attività eċċessiva (ADHD, attention deficit hyperactivity disorder) jew narkolepsija (magħrufa bħala ‘stimulanti')
English: It is recommended that HALDOL is not used alone in patients in whom depression is predominant.
Maltese: HALDOL ma jintużax waħdu f'pazjenti li fihom id-depressjoni hija predominanti.
English: In patients with first-episode schizophrenia, therapeutic response may be obtained at concentrations as low as 0.6 to 3.2 ng/ml, as estimated based on measurements of D2 receptor occupancy and assuming that a D2 receptor occupancy level of 60 to 80% is most appropriate for obtaining therapeutic response and limiting extrapyramidal symptoms.
Maltese: F'pazjenti bl-ewwel episodju ta' skiżofrenja, rispons terapewtiku jista' jinkiseb b'konċentrazzjonijiet baxxi ta' 0.6 sa 3.2 ng/ml, kif stmat abbażi ta' kejl tal-okkupanza tar-riċettur D2 u jekk wieħed jassumi li livell ta' okkupanza tar-riċettur D2 ta' 60 sa 80% huwa l-aktar xieraq biex jinkiseb rispons terapewtiku u jiġu limitati s-sintomi ekstrapiramidali.
English: • 2 to 5 mg intramuscularly.
Maltese: • Minn 2 sa 5 mg minn ġol-muskolu.
English: • The recommended doses are 0.5 to 3 mg/day in children aged 6 to 11 years and 0.5 to 5 mg/day in adolescents aged 12 to 17 years, administered orally in divided doses (2 to 3 times a day).
Maltese: • Id-dożi rrakkomandati huma 0.5 sa 3 mg/kuljum fi tfal u adolexxenti li għandhom minn 10 snin sa 17-il sena, mogħtija mill-ħalq maqsuma f'aktar minn doża waħda
English: Treatment of tic disorders, including Tourette's syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed
Maltese: Trattament ta' disturbi ta' tik, inkluż is-sindrom ta' Tourette, fi tfal u adolexxenti li għandhom minn 10 snin sa 17-il sena b'indeboliment sever wara li trattamenti edukattivi, psikoloġiċi u trattamenti farmakoloġiċi oħra jkunu fallew
English: Haloperidol has been associated with neuroleptic malignant syndrome: a rare idiosyncratic response characterized by hyperthermia, generalised muscle rigidity, autonomic instability, altered consciousness and increased serum creatine phosphokinase levels.
Maltese: Haloperidol ġie assoċjat ma' sindrom newrolettiku malinn: rispons idjosinkratiku rari kkaratterizzat minn ipertermja, riġidità mifruxa fil-muskoli, instabbiltà awtonomika, koxjenza mibdula u żieda fillivelli ta' creatine phosphokinase fis-serum.
English: Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder
Maltese: Trattament ta' aġitazzjoni psikomotorja akuta assoċjata ma' disturb psikotiku jew episodji manijaċi ta' disturb bipolari I
English: QTc prolongation and/or ventricular arrhythmias, in addition to sudden death, have been reported with haloperidol (see sections 4.3 and 4.8).
Maltese: Flimkien ma' mewt zoptu, ġew irrappurtati titwil tal-QTc u/jew arritmiji tal-ventrikulu b'haloperidol (ara sezzjonijiet 4.3 u 4.8).
English: The maximum dose is 5 mg/day.
Maltese: Id-doża massima hija ta' 5 mg/kuljum.
English: HALDOL is contraindicated in combination with medicinal products known to prolong the QTc interval (see section 4.3).
Maltese: HALDOL huwa kontraindikat flimkien ma' prodotti mediċinali magħrufa li jtawlu l-intervall QTc (ara sezzjoni 4.3).
English: Rhabdomyolysis
Maltese: Reazzjoni Avversa
English: Table 1: Haloperidol dose recommendations for adults aged 18 years and above
Maltese: Tabella 1: Rakkomandazzjonijiet għad-doża ta' Haloperidol għall-adulti li għandhom 18-il sena u aktar
English: • May be repeated hourly until sufficient symptom control is achieved.
Maltese: • Jista' jiġi ripetut kull siegħa sakemm jinkiseb kontroll suffiċjenti tas-sintomi.
English: HALDOL and associated names (see Annex I) 1 mg tablets HALDOL and associated names (see Annex I) 2 mg tablets HALDOL and associated names (see Annex I) 4 mg tablets HALDOL and associated names (see Annex I) 5 mg tablets HALDOL and associated names (see Annex I) 10 mg tablets HALDOL and associated names (see Annex I) 20 mg tablets
Maltese: HALDOL u ismijiet assoċjati (ara Anness I) 1 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 2 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 4 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 5 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 10 mg pilloli HALDOL u ismijiet assoċjati (ara Anness I) 20 mg pilloli
English: • Your dose will normally be between 0.5 mg and 3 mg each day.
Maltese: • Id-doża tiegħek is-soltu tkun bejn 0.5 mg u 3 mg kuljum.
English: Haloperidol can increase the CNS depression produced by alcohol or CNS-depressant medicinal products, including hypnotics, sedatives or strong analgesics.
Maltese: L-effett ta' haloperidol fuq prodotti mediċinali oħra Haloperidol jista' jżid id-depressjoni tas-CNS ikkaġunata mill-alkoħol jew prodotti mediċinali li jiddepressaw is-CNS, inkluż ipnotiċi, sedattivi jew analġeżiċi qawwija.
English: Gradual withdrawal of haloperidol is advisable (see section 4.4).
Maltese: inkluż haloperidol (ara sezzjoni 4.8).
English: • Problems with vision, such as blurred vision
Maltese: • Problemi bil-vista, bħal vista mċajpra
English: If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including HALDOL, must be considered.
Maltese: Jekk jidhru s-sinjali u s-sintomi ta' diskjneżja tardiva, għandu jitqies it-twaqqif talantipsikotiċi kollha inkluż HALDOL.
English: Do not take Haldol if:
Maltese: Tiħux Haldol jekk:
English: There is a risk in the treatment of manic episodes of bipolar disorder for patients to switch from mania to depression.
Maltese: Fit-trattament tal-episodji manjaċi tad-disturb bipolari hemm riskju li l-pazjenti jaqilbu minn manija għal depressjoni.
English: 3 drops
Maltese: 3 qatriet
English: • Rapid control of severe acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder when oral therapy is not appropriate.
Maltese: • Kontroll malajr ta' aġitazzjoni psikomotorja severa akuta assoċjata ma' disturb psikotiku jew episodji manijaċi ta' disturb bipolari I meta terapija orali ma tkunx xierqa.
English: The possible increase in intraocular pressure must be considered when anticholinergic medicinal products, including antiparkinson medicinal products, are administered concomitantly with HALDOL.
Maltese: Iż-żieda possibbli fil-pressjoni intraokulari għandha titqies meta prodotti mediċinali antikolinerġiċi, inkluż prodotti mediċinali kontra l-parkinson, jingħataw flimkien ma'
English: Limited plasma concentration data were established in paediatric studies including 78 patients with various disorders (schizophrenia, psychotic disorder, Tourette's syndrome, autism) who received oral haloperidol doses up to a maximum of 30 mg/day.
Maltese: Dejta limitata dwar konċentrazzjoni fil-plażma ġiet stabbilita fi studji pedjatriċi inkluż 78 pazjent b'disturbi varji (skiżofrenja, disturbi psikotiċi, sindrom ta' Tourette, awtiżmu) li rċivew dożi ta'
English: 2 mg/ml oral solution:
Maltese: HALDOL. soluzzjoni orali ta' 2 mg/ml:
English: Convulsion Parkinsonism Sedation Muscle contractions involuntary
Maltese: Parkinsoniżmu Sedazzjoni
English: Number of drops of HALDOL (dropper container)
Maltese: Numru ta' qtar ta' HALDOL (contenitur b'qattara)
English: • Depression, or you have bipolar disorder and start to feel depressed.
Maltese: • Depressjoni, jew inti għandek disturb bipolari u tibda tħossok depress/a.
English: Dyspnoea
Maltese: Distonja
English: • Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated.
Maltese: • Trattament ta' korea minn ħafifa sa moderata tal-marda ta' Huntington, meta prodotti mediċinali oħra ma jkunux effettivi jew ittollerati.
English: Visual disturbance
Maltese: Disturbi filqalb
English: Hyperprolactinaemia Inappropriate antidiuretic hormone secretion
Maltese: Sekrezzjoni mhux xierqa tal-ormon antidijuretiku
English: • Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated, and oral therapy is not appropriate.
Maltese: • Trattament ta' korea minn ħafifa sa moderata tal-marda ta' Huntington, meta prodotti mediċinali oħra ma jkunux effettivi jew ittollerati, u terapija orali ma tkunx xierqa.
English: As haloperidol is metabolised by the liver, dose adjustment and caution is advised in patients with hepatic impairment (see sections 4.2 and 5.2).
Maltese: Minħabba li haloperidol jiġi metabolizzat fil-fwied, hija rrakkomandata nofs id-doża tal-bidu u lkawtela f'pazjenti b'indeboliment tal-fwied (ara sezzjonijiet 4.2 u 5.2).
English: • Feeling confused
Maltese: • Tħossok konfuż
English: • Treatment of moderate to severe manic episodes associated with bipolar I disorder.
Maltese: • Trattament ta' episodji manjaċi minn moderati sa severi assoċjati ma' distub bipolari I.
English: • Serious mental health problem, such as believing things that are not true (delusions) or seeing,
Maltese: • Problemi serji ta' saħħa mentali, bħal temmen affarijiet li mhumiex veri (delużjonijiet)
English: Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer's dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others
Maltese: Trattament ta' aggressjoni persistenti u sintomi psikotiċi f'pazjenti b'dimenzja ta' Alzheimer minn moderata sa severa u dimenzja vaskulari meta trattamenti mhux farmakoloġiċi jkunu fallew u meta jkun hemm riskju li l-persuna tweġġa' lilha nnifisha jew lill-ħaddieħor
English: • Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder.
Maltese: • Trattament ta' aġitazzjoni psikomotorja akuta assoċjata ma' disturb psikotiku jew episodji manijaċi ta' disturb bipolari I.
English: Rapid control of severe acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder when oral therapy is not appropriate
Maltese: Kontroll malajr ta' aġitazzjoni psikomotorja severa akuta assoċjata ma' disturb psikotiku jew episodji manijaċi ta' disturb bipolari I meta terapija orali ma tkunx xierqa
English: ml HALDOL (bottle with oral syringe)
Maltese: ml HALDOL (flixkun b'siringa tal-ħalq)
English: • May be repeated hourly until sufficient symptom control is achieved or up to a maximum of
Maltese: • Jista' jiġi ripetut kull siegħa sakemm jinkiseb kontroll suffiċjenti tas-sintomi jew sa massimu ta'
English: Trismus Muscle twitching
Maltese: Rimettar Nawsja Stitikezza
English: Table 2 lists adverse reactions as follows:
Maltese: Tabella 2 telenka r-reazzjonijiet avversi kif ġej:
English: Haldol can cause problems with the heart, problems controlling body or limb movements and a serious side effect called ‘neuroleptic malignant syndrome'.
Maltese: Haldol jista' jikkawża problemi bil-qalb, problemi bil-kontroll ta' movimenti tal-ġisem jew tad dirgħajn u r-riġlejn u effett sekondarju serju msejjaħ ‘sindrom newrolettiku malinn'.
English: In addition, the safety of haloperidol decanoate was evaluated in 410 patients who participated in 3 comparator studies (1 comparing haloperidol decanoate versus fluphenazine and 2 comparing the decanoate formulation to oral haloperidol), 9 open label studies and 1 dose response study.
Maltese: Barra dan, is-sigurtà ta' haloperidol decanoate ġiet ivvalutata f'410 pazjenti li pparteċipaw fi 3 studji ta' tqabbil bejn mediċini (1 li qabbel haloperidol decanoate versus fluphenazine u 2 li qabblu lformulazzjoni ta' decanoate mal-formolazzjoni ta' haloperidol mill-ħalq), 9 studji fejn kemm linvestigaturi kif ukoll l-individwi kienu jafu liema sustanza qed tintuża u studju wieħed ta' rispons tad-doża.
English: Medicinal products that may decrease haloperidol plasma concentrations
Maltese: Prodotti mediċinali li jistgħu jżidu l-konċentrazzjonijiet ta' haloperidol fil-plażma
English: Sodium valproate is known to inhibit glucuronidation, but does not affect haloperidol plasma concentrations.
Maltese: Sodium valproate huwa magħruf li jinibixxi glukuronidazzjoni, iżda ma jaffetwax il konċentrazzjonijiet ta' haloperidol fil-plażma.
English: • Problems having sex.
Maltese: • Ipokalimja mhux ikkoreġuta.
English: The HALDOL 2 mg/ml oral solution in a dropper container is intended to be used for single doses up to 2 mg haloperidol (equivalent to 20 drops).
Maltese: Is-soluzzjoni orali ta' HALDOL 2 mg/ml f'kontenitur b'qattara qegħda biex tintuża għal dożi waħdiet sa 2 mg haloperidol (ekwivalenti għal 20 qatra).
English: 2 drops
Maltese: 2 qatriet
English: There have been very rare reports of acute withdrawal symptoms (including nausea, vomiting and insomnia) after abrupt withdrawal of high doses of antipsychotics.
Maltese: Kien hemm rapporti rari ħafna ta' sintomi akuti ta' twaqqif (inkluż nawsja, rimettar u insomnja) wara twaqqif f'daqqa ta' dożi għoljin ta' antipsikotiċi.
English: It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity.
Maltese: Huwa antagonist ċentrali potenti tar-riċettur tat-tip 2 tad-dopamina, u bid-dożi rrakkomandati, għandu attività adrenerġika alpha-1 baxxa u m'għandu l-ebda attività antiistaminerġika jew antikolinerġika.
English: • Persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated.
Maltese: • Aggressjoni persistenti severa fi tfal u adolexxenti li għandhom minn 6 snin sa 17-il sena b'awtiżmu jew disturbi pervażivi tal-iżvilupp, meta trattamenti oħra jkunu fallew jew ma jkunux ittollerati.
English: Pancytopenia Agranulocytosis Thrombocytopenia Neutropenia
Maltese: Akajneżja Riġidità bħal ta' rota tal-ingranaġġ
English: Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated
Maltese: Trattament ta' korea minn ħafifa sa moderata tal-marda ta' Huntington, meta prodotti mediċinali oħra ma jkunux effettivi jew ittollerati
English: • Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer's dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.
Maltese: • Trattament ta' aggressjoni persistenti u sintomi psikotiċi f'pazjenti b'dimenzja ta' Alzheimer minn moderata sa severa u dimenzja vaskulari meta trattamenti mhux farmakoloġiċi jkunu fallew u meta jkun hemm riskju li l-persuna tweġġa' lilha nnifisha jew lill-ħaddieħor
English: Adverse reaction frequencies are based on (or estimated from) clinical trials or epidemiology studies with haloperidol, and classified using the following convention:
Maltese: Il-frekwenzi tar-reazzjonijiet avversi huma bbażati fuq (jew stmati minn) provi kliniċi jew studji epidemjoloġiċi b'haloperidol, u kklassifikati bl-użu tal-konvenzjoni li ġejja:
English: • Do not take a double dose.
Maltese: • Tiħux doża doppja.
English: Conversion table for HALDOL 10 mg/ml oral solution mg haloperidol
Maltese: Tabella ta' konverżjoni għas-soluzzjoni orali ta' HALDOL 10 mg/ml mg haloperidol
English: • The maximum recommended dose is 5 mg/day.
Maltese: • Id-doża massima rrakkomandat huwa 5 mg/kuljum.
English: A linear relationship exists between haloperidol dose and plasma concentrations in adults.
Maltese: Teżisti relazzjoni lineari bejn id-doża ta' haloperidol u l-konċentrazzjonijiet fil-plażma fl-adulti.
English: Conversion table for HALDOL 2 mg/ml oral solution mg haloperidol
Maltese: Tabella ta' konverżjoni għas-soluzzjoni orali ta' HALDOL 2 mg/ml mg haloperidol
English: Amenorrhoea Galactorrhoea Dysmenorrhoea Breast pain Breast discomfort
Maltese: Amenorrea Galactorrea Dismenorrea
English: Priapism Gynaecomastia
Maltese: Ginekomastja
English: Urinary retention
Maltese: Iperprolaktinimja
English: These include mental health problems (such as schizophrenia and bipolar disorder) and behavioural problems.
Maltese: Dawn jinkludu problemi ta' saħħa mentali (bħal skiżofrenja u disturb bipolari) u problemi ta' mġieba.
English: The influence of hepatic impairment on the pharmacokinetics of haloperidol has not been evaluated.
Maltese: Ir-riżultati qegħdin fil-varjabilità osservata tal farmakokinetika ta' haloperidol.
English: Acute treatment of delirium when non-pharmacological treatments have failed
Maltese: Trattament akut ta' delirju meta jkunu fallew trattamenti mhux farmakoloġiċi
English: Conversion table for HALDOL 10 mg/ml oral solution mg haloperidol ml HALDOL (bottle with oral syringe)
Maltese: Tabella ta' konverżjoni għas-soluzzjoni orali ta' HALDOL 10 mg/ml mg haloperidol ml HALDOL (flixkun bis-siringa tal-ħalq)
English: Table 3: Conversion table for HALDOL 10 mg/ml oral solution mg haloperidol Number of drops of HALDOL (dropper container)
Maltese: Tabella 3: Tabella ta' konverżjoni għas-soluzzjoni orali ta' HALDOL 10 mg/ml mg haloperidol
English: Conversion table for HALDOL 2 mg/ml oral solution mg haloperidol ml HALDOL (bottle with oral syringe)
Maltese: Tabella ta' konverżjoni għas-soluzzjoni orali ta' HALDOL 2 mg/ml mg haloperidol ml HALDOL (flixkun bis-siringa tal-ħalq)
English: • Persistent and painful erection of the penis
Maltese: • Erezzjoni tal-pene persistenti u bl-uġigħ
English: Hyperthermia Oedema Gait disturbance
Maltese: Effetti sekondarji oħra
English: • To help control movements in Huntington's disease
Maltese: • Biex jgħin jikkontrolla movimenti fil-marda ta' Huntington
English: HALDOL and associated names (see Annex I) 5 mg/ml solution for injection
Maltese: HALDOL u ismijiet assoċjati (ara Anness I) 5 mg/ml soluzzjoni għall-injezzjoni [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: NAME OF THE MEDICINAL PRODUCT HALDOL and associated names (see Annex I) 20 mg tablets [See Annex I - To be completed nationally] haloperidol
Maltese: HALDOL u ismijiet assoċjati (ara Anness I) 20 mg pilloli [Ara Anness I - Biex timtela mill-pajjiż partikolari] haloperidol
English: The following problems may occur in newborn babies of mothers that take Haldol in the last 3 months of their pregnancy (the last trimester):
Maltese: Il-problemi li ġejjin jistgħu jseħħu fi trabi tat-twelid ta' ommijiet li jieħdu Haldol fl-aħħar 3 xhur tattqala tagħhom (l-aħħar trimestru):
English: Drug withdrawal syndrome neonatal (see section 4.6)
Maltese: Sindrom ta' twaqqif ta' sustanza li tivvizzja fit-trabi tat-twelid (ara sezzjoni 4.6)
English: However, hepatic impairment may have significant effects on the pharmacokinetics of haloperidol because it is extensively metabolised in the liver.
Maltese: Indeboliment tal-kliewi L-influwenza ta' indeboliment tal-kliewi fuq il-farmakokinetika ta' haloperidol ma ġietx ivvalutata.
English: Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated, and oral therapy is not appropriate
Maltese: Trattament ta' korea minn ħafifa sa moderata tal-marda ta' Huntington, meta prodotti mediċinali oħra ma jkunux effettivi jew ittollerati, u terapija orali ma tkunx xierqa
English: Cogwheel rigidity Masked facies
Maltese: Kif għandek tuża Haldol
English: If concomitant treatment with an antiparkinson medicinal product is required, it may have to be continued after stopping HALDOL if its excretion is faster than that of haloperidol in order to avoid the development or aggravation of extrapyramidal symptoms.
Maltese: Jekk ikun meħtieġ trattament konkomittanti bi prodott mediċinali kontra l-parkinson, huwa jista' jkollu jitkompla wara li HALDOL jitwaqqaf jekk it-tneħħija tiegħu mill-ġisem tkun aktar malajr minn dik ta' haloperidol sabiex jiġi evitat l-iżvilupp jew l-aggravar tas-sintomi ekstrapiramidali.